Novel Role for p90 Ribosomal S6 Kinase in the Regulation of Cardiac Myofilament Phosphorylation*§

Received for publication, November 11, 2010. Published, JBC Papers in Press, December 9, 2010, DOI 10.1074/jbc.M110.202713

Friederike Cuello‡1, Sonya C. Bardswell‡, Robert S. Haworth‡, Elisabeth Ehler‡, Sakthivel Sadayappan‡, Jonathan C. Kentish‡, and Metin Avkiran‡1

From the ‡King’s College London British Heart Foundation Centre, Cardiovascular Division, St. Thomas’ Hospital, London SE1 7EH, United Kingdom and the §Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, Illinois 60153

In myocardium, the 90-kDa ribosomal S6 kinase (RSK) is activated by diverse stimuli and regulates the sarcoplasmic Na+/H+ exchanger through direct phosphorylation. Only limited information is available on other cardiac RSK substrates and functions. We evaluated cardiac myosin-binding protein C (cMyBP-C), a sarcomeric regulatory phosphoprotein, as a potential RSK substrate. In rat ventricular myocytes, RSK activation by endothelin 1 (ET1) increased cMyBP-C phosphorylation at Ser282, which was inhibited by the selective RSK inhibitor D1870. Neither ET1 nor D1870 affected the phosphorylation status of Ser273 or Ser302, cMyBP-C residues additionally targeted by cAMP-dependent protein kinase (PKA). Complementary genetic gain- and loss-of-function experiments, through the adenoviral expression of wild-type or kinase-inactive RSK isofoms, confirmed RSK-mediated phosphorylation of cMyBP-C at Ser282. Kinase assays utilizing as substrate wild-type or mutated (S273A, S282A, S302A) recombinant cMyBP-C fragments revealed direct and selective Ser282 phosphorylation by RSK. Immunolabeling with a Ser(P)282 antibody and confocal fluorescence microscopy showed RSK-mediated phosphorylation of cMyBP-C across the C-zones of sarcomeric A-bands. In chemically permeabilized mouse ventricular muscles, active RSK again induced selective Ser282 phosphorylation in cMyBP-C, accompanied by significant reduction in Ca2+ sensitivity of force development and significant acceleration of cross-bridge cycle kinetics, independently of troponin I phosphorylation at Ser22/Ser23. The magnitudes of these RSK-induced changes were comparable with those induced by PKA, which phosphorylated cMyBP-C additionally at Ser273 and Ser302. We conclude that Ser282 in cMyBP-C is a novel cardiac RSK substrate and its selective phosphorylation appears to regulate cardiac myofilament function.

The 90-kDa ribosomal S6 kinase (p90 RSK or RSK), also known as the mitogen-activated protein kinase-activated protein kinase-1 (MAPKAP-K1) family, comprises three principal isoforms: RSK1 (encoded by the RPS6KA1 gene), RSK2 (RPS6KA3), and RSK3 (RPS6KA2) (1). An additional isoform, RSK4 (RPS6KA6), has also been identified, but evidence suggests that this isoform behaves in an atypical manner in terms of its expression and function (2). All four isoforms are characterized by the presence of two functionally distinct kinase domains, the N-terminal kinase (NTK) and the C-terminal kinase (CTK) (1). RSKs bind and are activated by extracellular signal-regulated kinases 1 and 2 (ERK1/2) through a sequential process that involves ERK-mediated phosphorylation of the CTK, CTK-mediated autophosphorylation of the RSK hydrophobic motif to create a docking site for 3′-phosphoinositide-dependent kinase 1 (PDK1), and PDK1-mediated phosphorylation of the NTK (1). Although the only known substrate of the CTK is the RSK hydrophobic motif, multiple cellular substrates are phosphorylated by the NTK, a serine/threonine kinase of the AGC kinase family (1). Consistent with this, RSK activity has been proposed to play important regulatory roles in diverse cellular processes, including cell survival, growth, proliferation, and migration (1). Pharmacological inhibition of the RSK NTK has been shown to inhibit the proliferation of cancer cell lines (3), and a recent study has shown that RSK activity is necessary to induce epithelial cell motility and invasiveness (4). These and other complementary observations suggest that RSK may represent a viable drug target in some carcinomas (5, 6).

With regard to cardiovascular biology, considerable data have accumulated to indicate that RSK phosphorylates the Na+/H+ exchanger (NHE) isoform 1 (NHE1) at Ser703 (7) and thereby mediates increased cardiac sarcoplasmal NHE activity in response to diverse stress stimuli (8–11). In view of the proposed involvement of NHE1 activity in the pathogenesis of cardiac ischemic injury (12) and remodeling (13), such findings have led to the consideration of RSK as a potential therapeutic target for cardiac protection (14). Nevertheless, only limited information is available on other RSK substrates and functions in the heart, which may include roles in the phosphorylation of the inhibitory subunit of cardiac troponin I (cTnI) (15), the induction of prorenin-converting enzyme in ischemic and diabetic myocardium (16), and the prolongation of the on-line version of this article (available at http://www.jbc.org) contains supplemental Methods and additional references and a table.

© 2011 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
Also inhibited ET1-induced cMyBP-C phosphorylation at Ser282 (Fig. 1B). However, unlike U0126, D1870 increased MEK-mediated phosphorylation of ERK, ERK-mediated phosphorylation of the RSK CTK, and CTK-mediated autophosphorylation of the RSK linker region (Fig. 1B), in the basal state and following ET1 stimulation, which is consistent with recent evidence that the RSK NTK participates in a negative feedback loop that regulates the MEK-ERK-RSK pathway (25, 26). The consistent effects of U0126 and D1870 on ET1-induced cMyBP-C phosphorylation at Ser282, together with the contrasting effects of these inhibitors on the activation of upstream elements of the relevant pathway, suggest that Ser282 may be a novel substrate for the RSK NTK in cardiac myocytes, on the assumption that D1870 specifically inhibits the NTK of RSK isoforms that are expressed in these cells.

To investigate the effects of D1870 on the NTK activity of endogenous RSK isoforms in ARV, we immunoprecipitated these isoforms using a pan-RSK antibody and carried out an in vitro kinase assay, utilizing as substrate a recombinant protein that contains the C-terminal regulatory domain of the Na+ /H+ exchanger NHE1, which is an established substrate for the RSK NTK (11). D1870, when added to the assay mixture after immunoprecipitation, completely abolished NHE1 phosphorylation, reflecting potent inhibition of the NTK activity of immunoprecipitated RSK isoforms (Fig. 2A, top panel). Interestingly, pretreatment of ARV with D1870 prior to ET1 stimulation and RSK immunoprecipitation also inhibited NHE1 phosphorylation, likely reflecting the high affinity of D1870 for the RSK NTK (Fig. 2A, bottom panel). These findings confirm that D1870 is a potent inhibitor of the NTK of endogenous RSK isoforms in ARV.

We next explored whether RSK could directly phosphorylate cMyBP-C at Ser282, in a manner that is inhibited by D1870. In an in vitro kinase assay, immunoprecipitated endogenous RSK isoforms (data not shown) and recombinant active RSK2 (Fig. 2B) catalyzed marked phosphorylation of Ser282 in a recombinant substrate protein comprising the c1c2 domain (amino acids 53–362) of human cMyBP-C. RSK2-mediated Ser282 phosphorylation was abolished by D1870 and inhibited to a lesser extent by H89 (Fig. 2B), which is a broad spectrum inhibitor that targets multiple kinases including RSK2 (27) but is commonly used to inhibit PKA. As expected, the PKA catalytic subunit also induced marked phosphorylation of Ser282 in the recombinant substrate protein comprising the c1c2 domain; however, such phosphorylation was unaffected by D1870 but completely abolished by H89 (Fig. 2B). These findings indicate that the RSK NTK can directly phosphorylate cMyBP-C at Ser282 and that D1870 does not inhibit PKA. The selectivity of D1870 was further confirmed in intact ARV, in which pretreatment with this inhibitor had no effect on the phosphorylation of cTnI at Ser22/Ser23 (Fig. 2C, left panel) following β-adrenoreceptor stimulation by isoproterenol, a response that is mediated by PKA. D1870 also had no effect on ET1-induced phosphorylation of cTnI at the same sites (Fig. 2C, right panel), which occurs through the PKC-PKD signaling axis (19, 20). Taken together, our data indicate that D1870 is a potent and selective inhibitor of the RSK NTK in vitro and in cardiac repolarization in response to reactive oxygen species (17).

In the present study, we provide evidence from complementary genetic, biochemical, pharmacological, and physiological experiments for a novel cardiac RSK substrate, namely the sarcomeric protein cardiac myosin-binding protein C (cMyBP-C), through the phosphorylation of which RSK regulates myofilament function. Specifically, our data indicate that RSK phosphorylates cMyBP-C selectively at Ser282 (amino acid numbering refers to the mouse sequence) and that such phosphorylation is associated with reduced myofilament Ca2+ sensitivity and accelerated cross-bridge cycle kinetics in ventricular myocardium.

**RESULTS**

In a previous study on myofilament protein phosphorylation by protein kinase D (PKD) (19), we observed an increase in cMyBP-C phosphorylation at Ser282 in adult rat ventricular myocytes (ARVM) exposed to ET1, which occurred independently of cellular PKD activity. The amino acid sequence immediately N-terminal to Ser282 in cMyBP-C (AGRRRTS in mouse and GGRRIS in human; bold indicates the phosphorylated Ser residue) conforms to one of the two motifs that are commonly targeted in RSK NTK substrates (RXRXXX or RRXS; bold indicates the phosphorylated Ser residue and underlined indicates the required Arg residues) (22, 23). Furthermore, in cardiac myocytes, ET1 is a potent activator of the MEK-ERK-RSK signaling pathway (18). These observations led us to explore the potential role of the MEK-ERK-RSK pathway in ET1-induced cMyBP-C phosphorylation at Ser282, initially through a pharmacological approach. U0126, a selective inhibitor of MEK (24), inhibited ET1-induced cMyBP-C phosphorylation at Ser282 (Fig. 1A). As expected, U0126 also inhibited MEK-mediated phosphorylation of ERK at Thr202/Tyr204, ERK-mediated phosphorylation of the RSK CTK at Thr577, and CTK-mediated autophosphorylation of the RSK linker region at Ser386 (Fig. 1A). To explore the role of the RSK NTK, relative to its upstream activator kinases MEK, ERK, and the RSK CTK, in ET1-induced cMyBP-C phosphorylation at Ser282, we also investigated the effects of D1870, a recently characterized selective inhibitor of the RSK NTK in RSK1 and RSK2 isoforms (25). Like U0126, D1870 also inhibited ET1-induced cMyBP-C phosphorylation at Ser282 (Fig. 1B). However, unlike U0126, D1870 increased MEK-mediated phosphorylation of ERK, ERK-mediated phosphorylation of the RSK CTK, and CTK-mediated autophosphorylation of the RSK linker region (Fig. 1B), in the basal state and following ET1 stimulation, which is consistent with recent evidence that the RSK NTK participates in a negative feedback loop that regulates the MEK-ERK-RSK pathway (25, 26). The consistent effects of U0126 and D1870 on ET1-induced cMyBP-C phosphorylation at Ser282, together with the contrasting effects of these inhibitors on the activation of upstream elements of the relevant pathway, suggest that Ser282 may be a novel substrate for the RSK NTK in cardiac myocytes, on the assumption that D1870 specifically inhibits the NTK of RSK isoforms that are expressed in these cells.

**EXPERIMENTAL PROCEDURES**

Expanded methodology is provided in the supplemental Methods. Previously published methods were used for key techniques such as the isolation and culture of ventricular myocytes from the adult rat heart (18), adenoviral vector construction and myocyte infection (11, 19), in vitro phosphorylation of recombinant and native proteins (20, 21), immunoblot analysis (20), immunolabeling and confocal microscopy (21), and assessment of myofilament function in skinned mouse ventricular trabeculae (21). Quantitative data are given as mean ± S.E. Statistical comparisons were by paired or unpaired Student’s t test, as appropriate, when comparing data between two groups, or by analysis of variance (ANOVA) followed by the Bonferroni test, when comparing data between multiple groups. p < 0.05 was considered significant.
RSK Regulation of Cardiac Myofilaments

A. Effects of U0126

| cMyBP-C phosphorylation | ERK phosphorylation | RSK CTK phosphorylation | RSK autophosphorylation |
|-------------------------|---------------------|-------------------------|-------------------------|
| vehicle                 | U0126               | vehicle                 | U0126                   |

IB: pS282 cMyBP-C
IB: pT202/ Y204 ERK
IB: RSK
IB: RSK

B. Effects of D1870

| cMyBP-C phosphorylation | ERK phosphorylation | RSK CTK phosphorylation | RSK autophosphorylation |
|-------------------------|---------------------|-------------------------|-------------------------|
| vehicle                 | D1870               | vehicle                 | D1870                   |

IB: pS282 cMyBP-C
IB: pT202/ Y204 ERK
IB: RSK
IB: RSK

FIGURE 1. Effects of the MEK inhibitor U0126 (A) or the RSK inhibitor D1870 (B) on ET1-induced phosphorylation of cMyBP-C at Ser282, ERK at Thr202/Tyr204, RSK at Thr577, or RSK at Ser386 in ARVM. Cells were exposed to vehicle control or ET1 (50 nM for 10 min) following pretreatment with vehicle, U0126 (3 μM for 10 min) or D1870 (1 μM for 60 min). cMyBP-C, ERK, or RSK phosphorylation status was determined by immunoblot (IB) analysis using the indicated phosphospecific antibodies, with protein loading confirmed by immunoblot analysis using antibodies against total protein. Individual immunoblots illustrate representative experiments, and bar charts show quantitative data (n = 6 – 8). *, p < 0.05 versus corresponding control (con) group. Error bars, S.E.

intact ARVM and that its effects on cMyBP-C phosphorylation at Ser282 are likely to occur through this mechanism.

To investigate the role of individual RSK isoforms in cMyBP-C phosphorylation at Ser282, we next employed a complementary genetic approach, through the use of adenoviral vectors to heterologously express wild-type (wt) or kinase-inactive (ki) forms of RSK1 (RSK1wt and RSK1ki) and RSK2 (RSK2wt and RSK2ki) in ARVM. In control cells (which were infected with adenoviral vectors encoding β-galactosidase or enhanced GFP), ET1 once again induced a significant increase in cMyBP-C phosphorylation at Ser282, and this response was abolished by pretreatment of cells with D1870 (Fig. 3A). Relative to control cells, heterologous expression of RSK1wt or RSK2wt increased the basal phosphorylation of cMyBP-C at Ser282 and amplified the response to ET1, with D1870 exerting an inhibitory effect on both the basal and the ET1-induced phosphorylation (Fig. 3A). Importantly, heterologous expression of RSK1ki or RSK2ki at similar levels to their wt counterparts markedly attenuated the ET1-induced phosphorylation of cMyBP-C at Ser282, through a dominant negative effect, and any residual ET1 response was abolished by D1870 (Fig. 3A). These data provide evidence that Ser282 in cMyBP-C is a novel substrate for both RSK1 and RSK2 isoforms in cardiac myocytes. Intriguingly, heterologous expression of RSK1wt or RSK2wt also led to increased phosphorylation of cTnI at Ser22/Ser23, particularly following ET1 stimulation, in a manner that was inhibited by pretreatment with D1870 (Fig. 3B). These findings are consistent with a previous report of increased cTnI phosphorylation at Ser22/Ser23 in hearts of mice with cardiac-specific expression of an RSK1 transgene (15) and suggest that overexpression of RSK isoforms in myocardium may be associated with a loss of physiological substrate specificity. In this context, it is important to note that ARVM with endogenous levels of RSK expression (control cells in this particular set of experiments (Fig. 3B) and uninfected cells in the earlier experiments (Fig. 2C)) exhibited ET1-induced increases in cTnI phosphorylation at Ser22/Ser23 that were unaffected by D1870, indicating that such increases occurred through an RSK-independent pathway, most likely by PKD (19).
A. Effects of D1870 on RSK NTK activity

![Diagram showing effects of D1870 on RSK NTK activity]

B. Direct phosphorylation of cMyBP-C by RSK and PKA in vitro

![Diagram showing direct phosphorylation of cMyBP-C]

C. Effects of D1870 on cTnl phosphorylation by PKA or PKD

![Diagram showing effects of D1870 on cTnl phosphorylation]

**FIGURE 2.** A, effects of D1870 on RSK NTK activity, as reflected by phosphorylation of a recombinant NHE1 fusion protein by endogenous RSK immunoprecipitated from ARVM, in an *in vitro* kinase (IVK) assay. Vehicle or D1870 (10 nM) was added to the reaction mixture after exposure of ARVM to ET1 (50 nM for 10 min) to activate RSK and subsequent RSK immunoprecipitation ([top panel](#)) or ARVM were pretreated with vehicle or D1870 (1 μM) for 60 min before exposure to ET1 to activate RSK and subsequent RSK immunoprecipitation ([bottom panel](#)). NHE1 phosphorylation status was determined by immunoblot (IB) analysis using a phosphospecific antibody and equal amounts of immunoprecipitated RSK in each sample confirmed by immunoblot analysis using an antibody against total RSK. Data are representative of three independent experiments.

B, direct phosphorylation of cMyBP-C at Ser282 by RSK and PKA *in vitro*. A recombinant protein comprising the c1c2 fragment of human cMyBP-C was used as substrate in an *in vitro* kinase assay, in the presence or absence of D1870 (10 nM) or H89 (100 nM), and phosphorylation by the PKA catalytic subunit or RSK2 was detected by immunoblot analysis using Ser(P)282 phosphospecific cMyBP-C antibody. Equal protein loading was confirmed by Coomassie staining.

C, effects of D1870 on PKA-mediated ([left panel](#)) or PKD-mediated ([right panel](#)) phosphorylation of cTnl at Ser22/Ser23, in ARVM exposed to isoproterenol (ISO; 10 nM for 10 min) or ET1 (50 nM for 10 min), respectively. cTnl phosphorylation status was determined by immunoblot analysis using Ser(P)22/Ser(P)23 phosphospecific cTnl antibody, with protein loading confirmed by immunoblot analysis using an antibody against total cTnl. Individual immunoblots illustrate representative experiments, and *bar charts* show quantitative data (*n* = 6). *, *p* < 0.05 versus corresponding control (con) group. Error bars, S.E.
Although the experiments described above provide robust evidence that Ser282 in cMyBP-C is a novel RSK substrate, they do not exclude the possibility that other sites in cMyBP-C may also be RSK targets. To determine which of the phosphoacceptor sites in cMyBP-C that are established targets for PKA, namely Ser273, Ser282, and Ser302, are also direct substrates for RSK, we carried out further in vitro kinase assays using recombinant active RSK2 or the PKA catalytic subunit and recombinant substrate proteins comprising the human cMyBP-C c1c2 domain, in wt form or mutated to singly replace each relevant Ser residue with nonphosphorylatable Ala (S273A, S282A, S302A). When in vitro phosphorylation was performed in the presence of [γ-32P]ATP and detected by autoradiography, wt c1c2 protein was phosphorylated by both kinases in a time-dependent manner (Fig. 4A). PKA-mediated phosphorylation was partially attenuated by each mutation, whereas RSK2-mediated phosphorylation was unaffected by the S273A and S302A mutations and completely abolished by the S282A mutation (Fig. 4A). These findings are consistent with the established ability of PKA to phosphorylate cMyBP-C directly at all three sites and additionally indicate that, in this system, RSK2 phosphorylates the c1c2 domain only at Ser282. Indeed, at saturation, the stoichiometry of phosphorylation of wt c1c2 protein measured 1.3 ± 0.5 mol of phosphate/mol of substrate with RSK2 and 2.9 ± 0.4 mol of phosphate/mol of substrate with PKA (n = 6). Furthermore, when in vitro phosphorylation was performed in the presence of nonradiolabeled ATP and detected by immunoblotting, the Ser282 phosphorylation was completely abolished by the S282A mutation (Fig. 4B).
A. Time-course of RSK2- and PKA-mediated phosphorylation of wild-type and mutated cMyBP-C (c1c2)

B. Time-course of RSK2- and PKA-mediated Ser282 phosphorylation in wild-type and mutated cMyBP-C (c1c2)

C. Characterization of pSer273 and pSer302 cMyBP-C antibodies

D. cMyBP-C phosphorylation at Ser273 and Ser302 in ARVM

FIGURE 4. A, time course of RSK2- or PKA-mediated phosphorylation of wild-type (wt) and mutated cMyBP-C c1c2 domains. Recombinant proteins comprising the c1c2 fragment of human cMyBP-C, in wt form or carrying single Ser/Ala substitutions (S273A, S282A, or S302A), were used as substrate in an in vitro kinase (IVK) assay performed in the presence of [γ-32P]ATP, and phosphorylation by RSK2 or the PKA catalytic subunit was detected by autoradiography. B, time course of RSK2- or PKA-mediated Ser282 phosphorylation in wt and mutated cMyBP-C c1c2 domains. Experimental details are identical to those described in A, except that the in vitro kinase assay was performed in the presence of nonradiolabeled ATP, and phosphorylation by RSK2 or the PKA catalytic subunit was detected by immunoblot (IB) analysis using Ser(P)282 phosphospecific cMyBP-C antibody. In both A and B, protein loading was confirmed by Coomassie staining, and the data are representative of three independent experiments.

C. Characterization of pSer273 and pSer302 cMyBP-C antibodies. Recombinant proteins comprising the c1c2 fragment of human cMyBP-C, in wt form or carrying single Ser/Ala substitutions (S273A, S282A, or S302A), were used as substrate in an in vitro kinase assay performed in the presence of nonradiolabeled ATP, and phosphorylation by the PKA catalytic subunit or RSK2 was detected by immunoblot analysis using Ser(P)273 or Ser(P)302 phosphospecific antibodies. Equal protein loading was confirmed by Coomassie staining. D, ET1-induced phosphorylation of cMyBP-C at Ser273 and Ser302 in ARVM. Cells were exposed to vehicle (con) or ET1 (50 nM for 10 min), following pretreatment with vehicle or D1870 (1 μM for 60 min). cMyBP-C phosphorylation status was determined by immunoblot analysis using an antibody against total cMyBP-C. Cell extract from ARVM exposed to isoproterenol (ISO; 10 nM for 10 min) was used as a positive control. Data are representative of three independent experiments.

FEBRUARY 18, 2011 • VOLUME 286 • NUMBER 7 • JOURNAL OF BIOLOGICAL CHEMISTRY 5305

RSK Regulation of Cardiac Myofilaments
RSK Regulation of Cardiac Myofilaments

whereas both were markedly enhanced in response to isoproterenol (Fig. 4D). Taken together, the above data indicate that RSK exclusively phosphorylates Ser282 in the unique N-terminal insert of cMyBP-C both in vitro and in intact cardiac myocytes and thus behaves in a distinct manner from PKA, which additionally phosphorylates Ser273 and Ser302.

To explore the subcellular localization of cMyBP-C phosphorylation at Ser282 upon ET1-induced activation of endogenous RSK isoforms, we employed immunolabeling and confocal microscopy in conjunction with the Ser(P)282 phosphospecific antibody. Co-labeling of ARVM with antibodies that recognize cMyBP-C regardless of its phosphorylation status and α-actinin (an established Z-disc marker) revealed the expected decoration of the sarcomeres, with localization of cMyBP-C protein to the A-band, on either side of the central M-band between the Z-discs (Fig. 5A). Neither exposure to ET1 nor pretreatment with D1870 affected the sarcomeric localization of cMyBP-C (Fig. 5A). When similar co-labeling was performed using the Ser(P)282 phosphospecific antibody, no cMyBP-C signal was detectable in vehicle-treated ARVM, reflecting low basal phosphorylation (Fig. 5B). In ARVM exposed to ET1, however, the Ser(P)282 phosphospecific antibody decorated the sarcomeres with a pattern that was similar to that observed with the phosphorylation-insensitive cMyBP-C antibody, but at lower intensity (Fig. 5B). Importantly, such decoration of the sarcomeres with the Ser(P)282 phosphospecific cMyBP-C antibody after ET1 exposure was abolished by pretreatment of ARVM with D1870 (Fig. 5B). These findings indicate that, when activated, endogenous RSK isoforms in cardiac myocytes mediate cMyBP-C phosphorylation at Ser282 throughout the known subcellular localization of this sarcomeric protein.

Finally, to investigate the potential impact of RSK-mediated phosphorylation of cMyBP-C exclusively at Ser282 on cardiac myofilament function, we studied the effects of such phosphorylation on the Ca2+ sensitivity of force development and cross-bridge cycle kinetics in ventricular myocardium. Because RSK can also target cTnl at Ser22/Ser23 in vitro (15) and when overexpressed in myocytes (Fig. 3B) (15), we used skinned myocardium from transgenic mice that only express cTnl in which Ser22/Ser23 are substituted by nonphosphorylatable Ala (cTnl-Ala2) (21, 30), to preclude functional effects on the Ca2+ sensitivity of force development (Fig. 7, A and B) and cross-bridge cycle kinetics (Fig. 7C). In time-matched control experiments, no significant changes were observed in the Ca2+ sensitivity of force development or cross-bridge cycle kinetics in skinned trabeculae that were incubated for an identical time in the absence of either kinase (supplemental table). These findings indicate that RSK-mediated phosphorylation of Ser282 in cMyBP-C is paralleled by significant changes in key parameters of myofilament function, such as the Ca2+ sensitivity of force development and cross-bridge cycle kinetics, and that these changes are of comparable magnitude to those induced by PKA, which phosphorylates cMyBP-C additionally at Ser273 and Ser302.

![FIGURE 5. Confocal microscope images showing the localization of total cMyBP-C (A) or cMyBP-C phosphorylated at Ser282 (B), in ARVM exposed to vehicle (con) or ET1 (50 nM for 10 min), following pretreatment with vehicle or D1870 (1 μM for 60 min). The cells were additionally immunolabeled with an α-actinin antibody, to demarcate the Z-discs, and nuclei were stained with DAPI. The images were obtained from perinuclear regions of each cell. In the merged images, red indicates α-actinin labeling, green indicates total or Ser(P)282 cMyBP-C labeling, and the nuclei are stained blue. Scale bars, 10 μm.](https://doi.org/10.1074/jbc.M110.204614)
DISCUSSION

Phosphorylation of sarcomeric proteins is a key mechanism through which cardiac myofilament function is regulated in response to neurohormonal stimuli (31). The present study provides novel evidence that (i) the sarcomeric protein cMyBP-C is a direct substrate for RSK; (ii) RSK-mediated phosphorylation of cMyBP-C occurs selectively at Ser282; (iii) endogenous RSK isoforms in intact myocytes, upon their neurohormonal activation, mediate cMyBP-C phosphorylation at Ser282 across the expected A-band localization of this sarcomeric protein; and (iv) RSK-mediated phosphorylation of cardiac myofilaments reduces the Ca$_2^+$ sensitivity of force development and accelerates cross-bridge cycle kinetics independently of cTnI phosphorylation at Ser22/Ser23, most likely through phosphorylation of cMyBP-C at Ser282. Previous studies on the regulation and roles of RSK isoforms in the cardiovascular system have revealed that cellular RSK activity is increased in response to multiple stimuli of relevance to cardiovascular physiology and pathophysiology, such as catecholamines (via $\alpha_1$-adrenoceptors) (8, 11, 18), angiotensin II (32), ET1 (18), oxidative stress (33), intracellular acidosis (9), and ischemia/reperfusion (34). Furthermore, RSK expression and activity appear to be increased in animal models of heart failure and in failing human myocardium (35, 36). Although much attention to date has focused on RSK-mediated phosphorylation of NHE1 at Ser703 and the likely functional consequences of this regulatory pathway (10, 11, 14), novel cardiac substrates for RSK are beginning to emerge. Recent evidence has revealed that RSK phosphorylates Kv4.3, a component of the K$^+$ channel that carries the cardiac transient outward current ($I_{to}$), at Ser216 and Ser250, and that this mechanism inhibits $I_{to}$ and contributes to the prolongation of cardiac repolarization in response to oxidative stress (17). Our present data identify cMyBP-C as a novel substrate for RSK and provide evidence that RSK-mediated phosphorylation of cMyBP-C at Ser282 represents a hitherto unknown mechanism for regulating cardiac contractile function.

In recent years, a considerable amount of evidence has accumulated to suggest that the phosphorylation status of cMyBP-C is an important determinant of cardiac function in health and disease (see recent review by Barefield and Sadayappan in Ref. 37). Studies in genetically modified mice that express mutated cMyBP-C, in which Ser273, Ser282, and Ser302 (originally identified as phosphoacceptor residues targeted by PKA) (28) were concurrently replaced by nonphosphorylatable Ala (29, 38, 39) or phosphomimetic Asp (29, 40), indicate that phosphorylation of cMyBP-C is critically important in preserving sarcomeric integrity and myocardial contraction, in the basal state and following $\beta$-adrenergic stimulation or ischemia/reperfusion (29, 38 – 40). Importantly, some previous studies have also suggested that phosphorylation of cMyBP-C is not modified in myocardium from patients with hypertrophic cardiomyopathy associated with two distinct truncating mutations in MYBPC3 (43). Phosphorylation of cMyBP-C was
maintained in the presence of a significant reduction in the phosphorylation of cTnI at Ser22/Ser23, suggesting divergent regulation of signaling pathways that differentially regulate these functionally important sarcomeric phosphoproteins (43). Our data from the present study suggest that RSK provides an alternative to PKA for the phosphorylation of Ser282 in cMyBP-C, which may be of particular importance for the neurohormonal regulation of cMyBP-C phosphorylation under pathological conditions (such as heart failure) where the β-adrenoreceptor–PKA pathway is down-regulated (44). Indeed, under such conditions, RSK may act in concert with other kinases that are activated independently of the β-adrenoreceptor–PKA pathway (such as PKD, which we have shown recently to selectively target cMyBP-C at Ser302) (21), to allow regulation of cMyBP-C phosphorylation at multiple sites. In this context, it is interesting to note that the expression of both RSK and PKD appears to be increased in various models of cardiac hypertrophy and failure (35, 36, 45) and in failing human myocardium (35, 46).

Although the functional importance of cMyBP-C phosphorylation is now firmly established (37), there is only limited information available on the potential roles of individual phosphorylation sites. This may be partly because PKA, the predominant kinase that mediates cMyBP-C phosphorylation under most physiological circumstances, targets all three of Ser273, Ser282, and Ser302 (28). Nevertheless, at least in vitro, Ser282 phosphorylation appears to play a unique role in facilitating PKA-mediated phosphorylation of Ser273 and Ser302, potentially through a conformational change that renders the latter two sites more accessible (28). Importantly, emerging evidence from novel mouse models that express mutated cMyBP-C with selective replacement of Ser282 with nonphosphorylatable Ala or phosphomimetic Asp suggests that phosphorylation of this site is of functional importance also in the in vivo setting, in regulating both the phosphorylation of Ser273 and Ser302 and the contractile response following β-adrenergic stimulation (47). These observations raise the intriguing possibility that selective phosphorylation of Ser282 by RSK may prime the other sites for phosphorylation by distinct kinases, such as PKA, and thus have a broader functional impact. With respect to our present data on RSK-mediated regulation of myofilament function, it is interesting to note that, in our recent work in an identical preparation, selective phosphorylation of cMyBP-C at Ser302 by PKD was associated with

**FIGURE 7.** Effects of RSK2- and PKA-mediated phosphorylation on (A and B) the Ca^{2+} sensitivity of force development and (C) cross-bridge cycle kinetics, in skinned ventricular trabeculae from cTnl-Ala2 mice. A, mean force-pCa curves obtained before (pre; open circles) and after (post; filled circles) incubation of trabeculae with RSK2 (left panel) or PKA catalytic subunit (right panel). Force values were normalized to the maximum force, measured at pCa 4.5. B, mean pCa at 50% maximum force (pCa_{50}) obtained before (pre; open bars) and after (post; filled bars) incubation of trabeculae with RSK2 or PKA catalytic subunit. C, mean relative rate of force redevelopment (k_{tr}) at 50% maximum force obtained before (pre; open bars) and after (post; filled bars) incubation of trabeculae with RSK2 or PKA catalytic subunit. *, p < 0.05 versus corresponding pre-kinase value (n = 7; Student’s paired t-test). Error bars, S.E.
the acceleration of cross-bridge cycle kinetics without a change in myofilament Ca$^{2+}$ sensitivity (21). In contrast, in the present study, selective phosphorylation of cMyBP-C at Ser$^{282}$ by RSK was associated with both an acceleration of cross-bridge cycle kinetics and a reduction in myofilament Ca$^{2+}$ sensitivity. These observations suggest that individual phosphorylation of Ser$^{282}$ versus Ser$^{202}$ may have differential impact on cardiac myofilament function.

As touched upon earlier, RSK activity has been implicated in the regulation of multiple cellular processes associated with tumor development and invasiveness, such that RSK inhibition has been proposed as a novel approach to pharmacotherapy in some carcinomas (4–6). Potential for cardiotoxicity continues to be an issue of significant clinical concern in the application of kinase inhibitors in cancer therapy (48), and the emerging cardiac roles of RSK should help inform the development of RSK inhibitors in this arena. As a corollary, our data also show that RSK inhibition in cardiac myocytes leads to enhanced activity of upstream components of the MEK-ERK-RSK signaling pathway. This observation is consistent with evidence from other cell types that the RSK NTK participates in a negative feedback loop that regulates the MEK-ERK-RSK pathway (25, 26). This has implications regarding the impact of increased ERK activity following RSK inhibition on both cancer and cardiac cell biology.

To conclude, the present study has revealed a novel substrate and role for RSK in the regulation of cardiac contractile function. Further work is now required to identify the individual role of RSK activity and to decipher the integrated actions of multiple convergent kinase pathways in the regulation of cMyBP-C phosphorylation and cardiac function in vivo, in physiological and pathological settings.

REFERENCES

1. Anjum, R., and Blenis, J. (2008) Nat. Rev. Mol. Cell Biol. 9, 747–758
2. Dümmüller, B. A., Hauge, C., Silber, J., Yntema, H. G., Kruse, L. S., Kofoed, B., Hemmings, B. A., Alessi, D. R., and Frödin, M. (2005) J. Biol. Chem. 280, 13304–13314
3. Smith, J. A., Poteet-Smith, C. E., Xu, Y., Errington, T. M., Hecht, S. M., Young, M. A., Woloszynski, K. Y., Miano, E. J., Daulerio, A. J., Stradley, D. A., Feerer, W. S., Van Dyk, D. E., Pitts, W. J., Erb, A. R., Hobbs, F., and Cohen, P. T. (2000) Biochem. J. 351, 1–8
4. Takahashi, E., Abe, J., Berk, B. C., and Berk, B. C. (1999) EMBO J. 18, 1952–1960
5. Sadayappan, S., Gulick, J., Klevitsky, R., Lorens, J. N., Sargent, M., Molkentin, J. D., and Robbins, J. (2009) Circulation 119, 1253–1262
6. Pi, Y., Kemnitz, K. R., Zhang, D., Kranias, E. G., and Walker, J. W. (2002) Circ. Res. 90, 649–656
7. Solaro, R. J. (2008) J. Biol. Chem. 283, 26829–26833
8. Takeishi, Y., Abe, J., and Berk, B. C. (1997) Circ. Res. 81, 268–273
9. Snabaitis, A. K., Hearse, D. J., and Avkiran, M. (2002) Cardiovasc. Res. 53, 470–480
10. Takeishi, Y., Abe, J., Lee, J. D., Kawakatsu, H., Walsh, R. A., and Berk, B. C. (1999) Circ. Res. 85, 1164–1172
11. Takeishi, Y., Huang, Q., Abe, J., Che, W., Lee, J. D., Kawakatsu, H., Hoit, B. D., Berk, B. C., and Walsh, R. A. (2002) Cardiovasc. Res. 53, 131–137
12. Takeishi, Y., Huang, Q., Abe, J., Glassman, M., Che, W., Lee, J. D., Kawakatsu, H., Lawrence, E. G., Hoit, B. D., Berk, B. C., and Walsh, R. A. (2001) J. Mol. Cell. Cardiol. 33, 1637–1648
13. Baretfield, D., and Sadayappan, S. (2010) J. Mol. Cell. Cardiol. 48, 866–875
14. Sadayappan, S., Gulick, J., Osinska, H., Martin, L. A., Hahn, H. S., Dorn, G. W., 2nd, Klevitsky, R., Seidman, C. E., Seidman, J. G., and Robbins, J. (2005) Circ. Res. 97, 1156–1163
15. Tong, C. W., Stelzer, J. E., Greaser, M. L., Powers, P. A., and Moss, R. L. (2008) Circ. Res. 103, 974–982
16. Sadayappan, S., Osinska, H., Klevitsky, R., Lorens, J. N., Sargent, M., Molkentin, J. D., Seidman, C. E., Seidman, J. G., and Robbins, J. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 16918–16923
17. Jacques, A. M., Copeland, O., Messer, A. E., Gallon, C. E., King, K., McKenna, W. J., Tsang, V. T., and Marston, S. B. (2008) J. Mol. Cell. Cardiol. 45, 209–216
18. El-Armouche, A., Pohlmann, L., Schlossak, S., Starbatty, J., Yeh, Y. H., Nattel, S., Dobrev, D., Eschenhagen, T., and Carrier, L. (2007) J. Mol. Cell. Cardiol. 43, 223–229
19. van Dijk, S. J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J. M.,
RSK Regulation of Cardiac Myofilaments

Winegrad, S., Schlossarek, S., Carrier, L., ten Cate, F. J., Stienen, G. J., and van der Velden, J. (2009) *Circulation* **119**, 1473–1483

44. Lohse, M. J., Engelhardt, S., and Eschenhagen, T. (2003) *Circ. Res.* **93**, 896–906

45. Avkiran, M., Rowland, A. J., Cuello, F., and Haworth, R. S. (2008) *Circ. Res.* **102**, 157–163

46. Bossuyt, J., Helmstadter, K., Wu, X., Clements-Jewery, H., Haworth, R. S., Avkiran, M., Martin, J. L., Pogwizd, S. M., and Bers, D. M. (2008) *Circ. Res.* **102**, 695–702

47. Sadayappan, S., Gulick, J., Martin, L. A., Cuello, F., Avkiran, M., Lorenz, J. N., and Robbins, J. (2009) *Circulation* **120**, S870 (abstract)

48. Cheng, H., and Force, T. (2010) *Circ. Res.* **106**, 21–34